<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682952</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2018-KL034-01</org_study_id>
    <nct_id>NCT03682952</nct_id>
  </id_info>
  <brief_title>Evaluation of Nail Fold Microcirculation in CKD</brief_title>
  <official_title>Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluation of nailfold microcirculation in patients with chronic renal failure and its
      intervention therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to study the changes of Nailfold Microcirculation in patients with
      chronic renal failure, to clarify the correlation between the changes of Nailfold
      Microcirculation and renal function, and to explore whether nailfold microcirculation can be
      used as an indicator of renal microcirculation in patients with chronic renal failure, and to
      provide a noninvasive method for the clinical evaluation of renal microcirculation in
      patients with chronic renal failure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nailfold microcirculation morphological integral</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Nail fold capillary microscopy examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nailfold microcirculation blood flow integral</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Nail fold capillary microscopy examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nail fold microcirculation perivascular loop integral</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Nail fold capillary microscopy examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The content of blood serum creatinine</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The content of blood urea nitrogen</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling，uronoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The content of blood cystatin C</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The content of blood albumin</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantification of urinary protein</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Uronoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The content of hemoglobin</measure>
    <time_frame>Up to three and a half months</time_frame>
    <description>Intravenous blood sampling</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anemia control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Anemia patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy person</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil Injection</intervention_name>
    <description>Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost sodium tablets</intervention_name>
    <description>Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD patients

          -  Without dialysis

          -  Blood pressure ≤ 140/90mmHg

        Exclusion Criteria:

          -  Polycystic kidney

          -  Endocrine system disease

          -  Cardio-cerebrovascular disease

          -  Rheumatic immune disease

          -  Peripheral vascular disease

          -  Hematological diseases

          -  Respiratory disease

          -  Infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Leunissen KM, van den Berg BW, Cheriex EC, Slaaf DW, Reneman RS, van Hooff JP. Influence of fluid removal during haemodialysis on macro- and skin microcirculation. Haemodynamic pathophysiologic study of fluid removal during haemodialysis. Nephron. 1990;54(2):162-8.</citation>
    <PMID>2314527</PMID>
  </reference>
  <reference>
    <citation>Yuksel S, Pancar Yuksel E, Yenercag M, Soylu K, Zengin H, Gulel O, Meriç M, Aydin F, Senturk N, Sahin M. Abnormal nail fold capillaroscopic findings in patients with coronary slow flow phenomenon. Int J Clin Exp Med. 2014 Apr 15;7(4):1052-8. eCollection 2014.</citation>
    <PMID>24955181</PMID>
  </reference>
  <reference>
    <citation>Senet P, Fichel F, Baudot N, Gaitz JP, Tribout L, Frances C. [Nail-fold capillaroscopy in dermatology]. Ann Dermatol Venereol. 2014 Jun-Jul;141(6-7):429-37. doi: 10.1016/j.annder.2014.04.120. Epub 2014 Jun 2. Review. French.</citation>
    <PMID>24951141</PMID>
  </reference>
  <reference>
    <citation>Yuan SY. [Nail-fold microcirculatory flow in liver cirrhosis: diabetes mellitus and systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi. 1986 Aug;66(8):473-5, 512. Chinese.</citation>
    <PMID>3096534</PMID>
  </reference>
  <reference>
    <citation>Paparde A, Nēringa-Martinsone K, Plakane L, Aivars JI. Nail fold capillary diameter changes in acute systemic hypoxia. Microvasc Res. 2014 May;93:30-3. doi: 10.1016/j.mvr.2014.02.013. Epub 2014 Mar 6.</citation>
    <PMID>24607833</PMID>
  </reference>
  <reference>
    <citation>Schumann L, Korten G, Holdt B, Holtz M. Microcirculation of the fingernail fold in CAPD patients: preliminary observations. Perit Dial Int. 1996 Jul-Aug;16(4):412-6.</citation>
    <PMID>8863336</PMID>
  </reference>
  <reference>
    <citation>Hasegawa K, Pereira BP, Pho RW. The microvasculature of the nail bed, nail matrix, and nail fold of a normal human fingertip. J Hand Surg Am. 2001 Mar;26(2):283-90.</citation>
    <PMID>11279575</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Renal Disease</keyword>
  <keyword>Nail fold microcirculation</keyword>
  <keyword>Interventional therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
    <mesh_term>Beraprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

